GlassScriptPhysician profile
Michael Tao
NPI 1528558178
$3,413.22
in general payments reported to CMS, 2019-2025
21 companies · $86.82 in 2025
The $86.82 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $63.75 · 2022: $335 · 2023: $890 · 2024: $2,038 · 2025: $86.82.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,944 · Travel and Lodging: $1,071.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,944.34 |
| Travel and Lodging | $1,070.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $1,475.21 | 2024 | Scopis Ent, Clarifix Cryotherapy Device |
| Pfizer INC. | $417.88 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $394.85 | 2022-2024 | Jardiance |
| Chiesi USA, INC. | $217.79 | 2023 | Kengreal, Cleviprex |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $146.12 | 2023-2025 | Lifevest |
| Medtronic, INC. | $131.99 | 2024 | Cobalt Dr Mri Surescan, Micra, Attain Command + Surevalve |
| Janssen Scientific Affairs, LLC | $128.42 | 2023-2024 | Xarelto |
| Janssen Pharmaceuticals, INC | $123.82 | 2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $81.45 | 2023-2024 | Eliquis, Camzyos |
| Amgen INC. | $40.44 | 2023-2024 | Repatha |
| Actelion Pharmaceuticals US, INC. | $35.40 | 2023-2025 | Opsumit, Uptravi, Ventavis |
| Alnylam Pharmaceuticals INC. | $28.51 | 2023 | Amvuttra |
| Novartis Pharmaceuticals Corporation | $27.08 | 2024 | |
| Kiniksa Pharmaceuticals International, Plc | $27.05 | 2024 | Arcalyst |
| Boston Scientific Corporation | $25.09 | 2023 | Watchman Access System |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shockwave Medical, INC | $22.20 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Terumo Medical Corporation | $22.13 | 2023 | Angio-Seal |
| Heartflow, INC. | $18.84 | 2024 | |
| B. Braun Interventional Systems INC. | $17.71 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $16.31 | 2021 | |
| Merck Sharp & Dohme LLC | $14.93 | 2023 | Verquvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Tao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.